Anti-interleukin-12 antibody for active Crohn's disease

New England Journal of Medicine

Volumn 351, Issue 20, 2004, Pages 2069-2079

  Mannon, Peter J ^a   Fuss, Ivan J ^a   Mayer, Lloyd ^c   Elson, Charles O ^d   Sandborn, William J ^e   Present, Daniel ^c   Dolin, Ben ^f   Goodman, Nancy ^g   Groden, Catherine ^a   Hornung, Ronald L ^h   Quezado, Martha ^b   Neurath, Markus F ⁱ   Salfeld, Jochen ^j   Veldman, Geertruida M ^j   Schwertschlag, Ullrich ^g   Strober, Warren ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f Health Advance Institute   (United States)

^g PFIZER INC   (United States)

^h Clinical Services Program   (United States)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j ABBOTT LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROHN DISEASE; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INFLAMMATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TH1 CELL; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLON; CROHN DISEASE; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 8344284998     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa033402     Document Type: Article

References (20)

1. Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin- 12 receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998;16:495-521.
2. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 1998;16:365-96.
3. Fais S, Capobianchi MR, Silvestri M, Mercuri F, Pallone F, Dianzani F. Interferon expression in Crohn's disease patients: increased interferon-γ and -α mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res 1994;14:235-8.
4. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
5. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169-78.
6. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-32.
7. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159:6276-82.
8. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interieukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
9. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-γ, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998;161:3143-9.
10. Simpson SJ, Shah S, Comiskey M, et al. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin-12/ signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on Interferon γ expression by T cells. J Exp Med 1998;187:1225-34.
11. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
12. Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest 1999;103:1151-8.
13. D'Haens GR, Geboes K, Peelers M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.
14. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-69.
15. Fracht DM. IL-23: acytokine that acts on memory T cells. Sci STKE 2002;2002(114): PE1.
16. Brombacher F, Kastelein RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol 2003;24:207-12.
17. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078-88.
18. Marth T, Kelsall BL. Regulation of interleukin-12 by complement receptor 3 signaling. J Exp Med 1997;185:1987-95.
19. Monteleone G, Parrello T. Monteleone I, Tammaro S, Luzza F, Pallone F. Interferon-gamma (IFN-gamma) and prostaglandin E2 (PGE2) regulate differently IL-12 production in human intestinal lamina propria mononuclear cells (LPMC). Clin Exp Immunol 1999;117:469-75.
20. Rennick DM, Fort MM. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL)-10(-/-) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2000;278:G829-G833.